There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Epizyme (NASDAQ: EPZM), Wright Medical Group (NASDAQ: WMGI) and Illumina (NASDAQ: ILMN) with bullish sentiments.
Epizyme (NASDAQ: EPZM)
In a report issued on June 11, Jotin Marango from Roth Capital maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $26. The company’s shares opened today at $16.05.
Marango said:
“We look to the data update at EHA this Friday to reinforce this proposition. In our view, so far taz looks superior to other oral options in R/R FL-MUT. We believe that the FL indication is fertile ground, especially for any new oral agent that is not a PI3K inhibitor (see our table on Page 2 inside comparing taz to the most advanced PI3K agents). In our view, taz goes above and beyond, and outperforms the PI3K class in both efficacy and safety/tolerability, based on data so far. We believe that taz will remain highly competitive in FL-MUT as long as its response rate remains above 70%. In perspective, approved oral agents approach 60% response rate in FL, while taz notched 82% in FL-MUT in the EHA abstract released in mid-May (n=22; data cut in mid-January).”
According to TipRanks.com, Marango is a 4-star analyst with an average return of 33.4% and a 60.7% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Aptevo Therapeutics Inc, and Aptose Biosciences.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.38, representing a 51.9% upside.
In a report issued on June 4, Oppenheimer also assigned a Buy rating to the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Wright Medical Group (NASDAQ: WMGI)
In a report released today, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on Wright Medical Group (NASDAQ: WMGI), with a price target of $30. The company’s shares opened today at $25.75.
Bijou observed:
“We reiterate our Overweight rating and a 12-month price target of $30 on shares of WMGI. We think WMGI is positioned to outperform expectations in 2018 with multiple drivers across each of its three primary segments (lower extremities, upper extremities, and biologics) to accelerate growth. We see WMGI’s valuation as attractive as we expect innovative products to help WMGI to capitalize on the evolving market trends. Valuation Summary We base our $30 price target on a 4.5x EV/Sales multiple on our 2019.”
According to TipRanks.com, Bijou is a 4-star analyst with an average return of 25.1% and a 71.0% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Stryker Corporation.
Wright Medical Group has an analyst consensus of Moderate Buy, with a price target consensus of $27.50.
Illumina (NASDAQ: ILMN)
In a report issued on June 11, Mark Massaro from Canaccord Genuity maintained a Buy rating on Illumina (NASDAQ: ILMN), with a price target of $316. The company’s shares opened today at $292, close to its 52-week high of $293.15.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.5% and a 64.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Idexx Laboratories.
Illumina has an analyst consensus of Strong Buy, with a price target consensus of $289.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
